Randomized, open-label, parallel-group phase III trial to prove an additional benefit of the full-spectrum cannabis extract VER-01 over opioids in patients with chronic non-specific low back pain for whom drug treatment is indicated and previous optimized treatments with non-opioid analgesics have not led to sufficient pain relief or were unsuitable due to contraindications or intolerance.
The test intervention VER-01 is a cannabis-based pain medication currently under clinical development that is expected to provide adequate pain relief while being better tolerated in long-term treatment compared to opioid analgesics. This study aims to demonstrate the superior tolerability, especially in terms of bowel function, of VER-01 compared to existing authorised and marketed opioid analgesics in patients with chronic non-specific low back pain. In addition, the safety and tolerability as well as the efficacy of VER-01 compared to opioid therapy will be evaluated.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
384
Standardized oleoresin of Cannabis sativa L. folium cum flore, THC-chemotype (cannabis leaves and - flowers), corresponding to 21 mg (-)-trans-Δ9-Tetra-hydrocannabinol (THC) per gram drug product
The patient-specific selection of the marketed opioid (based on standard of care and provided for this study) is at the discretion of the investigator and made at Visit 1, i.e., before randomization at Visit 2.
Rheumazentrum Prof. Dr. med. Gunther Neeck
Bad Doberan, Germany
Medizinische Hochschule Hannover (MHH)
Hanover, Germany
Risk of developing constipation
Number and proportion of constipation responders at the end of treatment phase (Visit 9). A constipation responder is defined as a patient with 1. a change from baseline (visit 2) in Bowel Function Index (BFI) total score of at least 15 points at Visit 9 and 2. a BFI total score of more than 28.8 at Visit 9.
Time frame: 190 days
Efficacy based on pain reduction
Number and percentage of 30% pain responders at study week 27 (last week of treatment phase) compared with the baseline score (study week -1)
Time frame: 190 days
Efficacy based on pain reduction in NE patients
Number and percentage of 30% pain responders in the subgroup of patients with a neuropathic pain component (painDETECT score \>18) at study week 27 compared with the baseline score (study week -1)
Time frame: 190 days
Efficacy based on pain reduction and interference with sleep
Number and percentage of patients with a 30% improvement of the mean daily low back pain interference with sleep score evaluated on an 11-point Numeric Rating Scale (NRS) at study week 27 compared with the baseline score (study week -1)
Time frame: 190 days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.